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OBJECTIVE—FFAR1/GPR40 is a G-protein–coupled receptor
expressed predominantly in pancreatic islets mediating free fatty
acid–induced insulin secretion. However, the physiological role
of FFAR1 remains controversial. It was previously reported that
FFAR1 knockout (Ffar1
/) mice were resistant to high-fat
diet–induced hyperinuslinemia, hyperglycemia, hypertriglyceri-
demia, and hepatic steatosis. A more recent report suggested that
although FFAR1 was necessary for fatty acid–induced insulin
secretion in vivo, deletion of FFAR1 did not protect pancreatic
islets against fatty acid–induced islet dysfunction. This study is
designed to investigate FFAR1 function in vivo using a third
line of independently generated Ffar1
/ mice in the C57BL/6
background.
RESEARCH DESIGN AND METHODS—We used CL-316,243,
a 3 adrenergic receptor agonist, to acutely elevate blood free
fatty acids and to study its effect on insulin secretion in vivo.
Ffar1
/ (wild-type) and Ffar1
/ (knockout) mice were placed
on two distinct high-fat diets to study their response to diet-
induced obesity.
RESULTS—Insulin secretion was reduced by 50% in Ffar1
/
mice, conﬁrming that FFAR1 contributes signiﬁcantly to fatty
acid stimulation of insulin secretion in vivo. However, Ffar1
/
and Ffar1
/ mice had similar weight, adiposity, and hyperinsu-
linemia on high-fat diets, and Ffar1
/ mice showed no improve-
ment in glucose or insulin tolerance tests. In addition, high-fat
diet induced comparable levels of lipid accumulation in livers of
Ffar1
/ and Ffar1
/ mice.
CONCLUSIONS—FFAR1 is required for normal insulin secre-
tion in response to fatty acids; however, Ffar1
/ mice are not
protected from high-fat diet–induced insulin resistance or he-
patic steatosis. Diabetes 57:2999–3006, 2008
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atty acids are involved in a diverse array of
physiological functions in a variety of tissues.
Many of the effects of fatty acids are thought to
be mediated by intracellular metabolites of long-
chain acyl-CoA esters. Evidence has accumulated over the
last few years, however, that at least some of the activities
attributed to fatty acids are mediated through their inter-
action with a number of G-protein–coupled receptors
designated FFAR1 (GPR40), FFAR2 (GPR43), FFAR3
(GPR41), GPR120, and GPR84. FFAR2 and FFAR3 are
activated by short-chain fatty acids, whereas FFAR1,
GPR84, and GPR120 are activated by medium- to long-
chain fatty acids (1). Among these receptors, FFAR1 and
GPR120 have drawn attention for their potential as thera-
peutic targets for metabolic disease (2–4).
Interest in FFAR1 intensiﬁed in 2005 when Steneberg et
al. (5) reported that mice lacking FFAR1 were resistant to
a number of the effects of a high-fat diet, including
hyperinuslinemia, hyperglycemia, hypertriglyceridemia,
and hepatic steatosis. Conversely, Steneberg et al. also
reported that transgenic mice overexpressing FFAR1 in
pancreatic islets developed diabetes, suggesting that sus-
tained signaling through FFAR1 could be detrimental.
Although it is known that fatty acids are important for
insulin secretion in normal individuals, it is also widely
recognized that chronically elevated fatty acids contribute
to pancreatic dysfunction (6). In this regard, Steneberg et
al. observed that insulin secretion from isolated Ffar1
/
islets was not impaired by 48-h exposure to palmitic acid
(5). They concluded that Ffar1
/ islets are protected
from the long-term negative effect of fatty acids and
suggested that FFAR1 antagonists might be used to pre-
vent and treat obesity-associated type 2 diabetes. Re-
cently, Latour et al. (7) reported the characterizations of a
second Ffar1
/ line. They showed that Ffar1
/ mice
had a 50% reduction in acute insulin secretion in re-
sponse to a bolus of injected Intralipid. Although Latour et
al. did not report on the effects of high-fat feeding in their
Ffar1
/ mice, they observed that male knockout mice on
a chow diet developed signiﬁcant (albeit slight) glucose
intolerance. They also showed that isolated islets from
Ffar1
/ mice were still subject to the impairment of the
insulin response after chronic exposure to fatty acids (7).
Except for the role of FFAR1 in mediating insulin secre-
tion, these ﬁndings stand in contrast to the report of
Steneberg et al. (5).
Here, we report metabolic phenotypes on a third, inde-
pendent line of Ffar1
/ mice generated in the C57BL/
6Ncrl (B6) background. We found that FFAR1 contributes
to 50% of fatty acid–mediated insulin release in vivo,
consistent with the previous report of Latour et al. (7). In
contrast to the previous observations by Steneberg et al.
(5), however, our Ffar1
/ mice are not protected from
the negative effects of high-fat diet. Ffar1
/ mice on a
high-fat diet became obese, developed insulin resistance,
and accumulated liver lipids to a similar extent when
compared with Ffar1
/ littermates. Taken together, our
data conﬁrm that FFAR1 is important for fatty acid–
mediated insulin secretion, but call into question its role in
mediating the toxic effects of free fatty acids on metabolic
diseases.
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Generation of Ffar1
/ mice in C57BL/6NCrl (B6) background.
Ffar1
/ mice were custom-generated by DeltaGen (Palo Alto, CA). Brieﬂy, a
targeting vector was designed to delete a 152-bp fragment corresponding to
position 143–294 of the open reading frame of the Ffar1 gene (NM_194057).
This segment was replaced with a Neomycin (neo) cassette. The vector was
electroporated into 129/OlaHsd-derived embryo stem (ES) cells, and G418-
resistant ES cell colonies were then picked and expanded for DNA analysis.
The correctly targeted ES cells were injected into blastocysts to generate
chimeric mice that were then mated to B6 females. Ffar1 heterozygous
(Ffar1
/) offspring were identiﬁed by a PCR-based screening strategy. The
PCR primers were designed to detect both wild-type (234-bp) and knockout
(399-bp) alleles. Oligonucleotide sequences were as follows: Ffar1 upstream
of the deleted region forward, 5-cccagcttggtctacactctccatc-3; Ffar1 down-
stream of the deleted region reverse, 5-gatggcttggtacccgaaggggaag-3; and neo
forward, 5-gggtgggattagataaatgcctgctct-3. Ffar1
/ mice were then interbred
to generate Ffar1
/ mice. Ffar1
/ mice were backcrossed to C57BL/6NCrl
mice for 10 generations to generate mice in a B6 background.
In vivo insulin secretion in response to acutely elevated free fatty
acids. Nonfasted Ffar1
/ and Ffar1
/ mice, age and sex matched, received
intraperitoneal injection of either saline or the 3-agonist CL-316,243 (Sigma-
Aldrich) at 1 mg/kg (8). Fifteen minutes after injection, 700 l blood was
collected from each mouse by cardiac puncture immediately after CO2
asphyxiation. To preserve glucagon-like peptide 1 (GLP-1), DPP-IV inhibitor
(Linco) was added to precooled blood collection tubes (BD Microtainer
365974; Becton Dickinson, Franklin Lakes, NJ) and plasma isolated by
centrifugation at 5,000 rpm for 10 min while maintaining a temperature of 4°C.
Aliquots of plasma samples were stored at 80°C until analysis. Plasma levels
of insulin and GLP-1 (7-36)amide were estimated using kits from Meso Scale
Discovery (Gaithersburg, MD). Leptin, amylin, and glucagon levels were
measured using the Lincoplex Luminex kits (Linco Research, St. Charles, MO).
Glucose, free fatty acids, and triglycerides were measured using commercial
kits from Wako Diagnostics (Richmond, VA).
High-fat diet–feeding studies. All mice under study were weaned onto Lab
Rodent Diet 20 (4.5% fat; PMI Nutrition International) and, unless speciﬁed,
were group housed in polycarbonate cages in a speciﬁc pathogen-free
environment on a 12-h light/dark cycle at a temperature of 22°C. In one study,
mice at N6 generation of backcrossing into B6 background were fed for 8
weeks with a Surwit diabetogenic diet (58% of calories from lard) or a
semipuriﬁed low-fat diet (D12450B; 10% of calories from fat; Research Diets,
New Brunswick, NJ) ad libitum. In a separate study, mice at N10 of
backcrossing into B6 background were fed with a semipuriﬁed diet with 60%
calories from fat (Research Diets). Body composition was assessed by nuclear
magnet resonance spectroscopy. Mice were killed by CO2 asphyxiation for
blood and tissue collection after 4 h fasting. Plasma glucose, fatty acid, and
triglyceride levels were measured as described above. Liver neutral lipids
(cholesterol ester, free cholesterol, and triglyceride) were analyzed by high-
performance liquid chromatography as previously described (9). All studies
were conducted in an American Association for Laboratory Animal Care–
accredited facility, according to protocols approved by the Schering-Plough
Research Institute Animal Care and Use Committee.
Glucose and insulin tolerance test. Blood was collected after 16 h of
fasting, and basal glucose levels were measured using a glucose oxidase
method (Glucometer Elite; Bayer, Elkhart, IN). After this measure, glucose (3
g/kg body wt) or insulin (0.75 mU/g body wt) was administered by intraperi-
toneal injection, and blood was collected from the tail vein at 20, 40, 60, 90,
and 120 min after dose for glucose determination.
Data analysis. Data are reported as means  SE. Statistical analyses were
performed with GraphPad Prism (version 4.00; GraphPad Software) using
unpaired Student’s t tests, one-way ANOVA, or two-way ANOVA, depending
on data structures. Speciﬁc methods used are indicated in the text. P values
	0.05 are considered statistically signiﬁcant.
RESULTS
To generate Ffar1
/ mice, a segment of the gene encod-
ing part of the second transmembrane domain, all of the
ﬁrst extracellular domain, and part of the third transmem-
brane domain of the FFAR1 protein was targeted by
homologous recombination (Fig. 1A). Targeted ES cells
were ﬁrst screened by PCR, and positive clones were
identiﬁed by Southern blotting using probes that hybridize
outside of and adjacent to the targeting construct arms.
Ffar1
/ mice were derived from a positive ES clone (ES
1315) (Fig. 1B). Examples of PCR genotypes from individ-
ual Ffar1
/ (wild-type), Ffar1
/ (Het), and Ffar1
/
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FIG. 1. Generation of Ffar1
/ mice. A: Schematic view of the regions depleted in Ffar1 gene. A 152-bp fragment corresponding to position
143–294 of the open reading frame of the Ffar1 gene (NM_194057) was replaced by a neo cassette. The two black bars below the bottom panel
represent the positions of the 5 and 3 probes used for Southern blotting. B: Southern blotting of ES cell clones. Shown are DNA samples from
two nontargeted ES clones and a targeted clone (ES 1315) digested by EcoRV and probed with a 5 probe and by HindIII and probed with a 3
probe, respectively. C: Representative PCR genotyping of DNA samples from tail clips of Ffar1
/ (WT) and Ffar1
/ (KO) mice. The WT allele
is 234 bp and the KO allele is 399 bp in size. D: Expression of Ffar1 mRNA in pancreatic islets and spleen of Ffar1
/ (WT) and Ffar1
/ (KO)
mice accessed by real-time quantitative PCR.
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3000 DIABETES, VOL. 57, NOVEMBER 2008(knockout) mice are shown in Fig. 1C. As assessed by
real-time quantitative RT-PCR, Ffar1
/ mice lack Ffar1
mRNA expression in pancreatic islets or in spleen (Fig.
1D). Ffar1
/ mice were born at the expected 1:2:1
Mendelian ratio and appeared healthy and fertile, and no
abnormalities were detected on gross examination. Under
chow-feeding conditions, we observed no overt difference
in metabolic phenotypes between Ffar1
/ and Ffar1
/
mice.
Fatty acid–stimulated insulin secretion was atten-
uated in Ffar1
/ mice in vivo. To examine the role
of FFAR1 in acute fatty acid–stimulated insulin release,
we used a selective 3-adrenergic receptor agonist
CL-316,243, which promotes lypolysis in rodent white
adipose tissue (10). When administrated by intraperitoneal
injection, CL-316,243 increases plasma free fatty acid
levels within 5 min, which in turn rapidly increases plasma
insulin levels (8). We injected saline and CL-316,243 (1
mg/kg) into Ffar1
/ and Ffar1
/ mice, respectively, and
collected blood samples to measure fatty acid and insulin
levels. We used one-way ANOVA to assess the changes
among the treatment groups. To test the differences be-
tween pairs of groups, we used t tests with Bonferroni
corrections to adjust for multiple comparisons. As shown
in Fig. 2, plasma fatty acid levels increased by approxi-
mately twofold in both Ffar1
/ and Ffar1
/ mice in
response to CL-316,243 injection (P 	 0.01). There was no
difference between Ffar1
/ and Ffar1
/ mice in the
A Free fatty acid Insulin
C Amylin Leptin
E GLP-1 Glucagon
B
D
F
FIG. 2. Plasma parameters of Ffar1
/ and Ffar1
/ mice in response to 3 agonist CL-316,243 (CL) injections. Mice received intraperitoneal
injection of either saline or CL-316,243. The four treatment groups are: Ffar1
/ mice receiving saline, Ffar1
/ mice receiving CL-316,243,
Ffar1
/ mice receiving saline, and Ffar1
/ mice receiving CL-316,243. n  5–8 mice per group. A: Free fatty acids. B: Insulin. C: Amylin. D:
Leptin. E: GLP-1 (7-36)amide. F: Glucagon. The data are analyzed by one-way ANOVA followed by t tests with Bonferroni correction. *P < 0.05;
**P < 0.01.
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 0.77, pairwise, two-tailed
t test), indicating that -adrenergic receptor–mediated
lipolysis in adipose tissue was not impaired in Ffar1
/
mice (Fig. 2A). In Ffar1
/ mice, this increase of free fatty
acid was accompanied by a 20-fold increase in plasma
insulin level (Fig. 2B). In the Ffar1
/ mice, insulin levels
were elevated about one-half as much as in the Ffar1
/
mice despite a similar increase in fatty acids (Fig. 2B; P 	
0.01, Ffar1
/ CL-316,243 vs. Ffar1
/ CL-316,243, t test
with Bonferroni correction). Similar results were obtained
in two other independent experiments (data not shown).
The data suggest that FFAR1 is responsible for 50% of
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FIG. 3. Metabolic characterizations of Ffar1
/ and Ffar1
/ mice after 8 weeks on a low-fat diet and high-fat diet. Ffar1
/ and Ffar1
/ mice
at N6 generation of backcrossing into B6 background were fed for 8 weeks on a Surwit diabetogenic diet (58% of calories from lard) or a
semipuriﬁed low-fat diet (10% of calories from fat) ad libitum. n  5 mice per group. Body weight and body fat were monitored biweekly. Food
intake was measured weekly. Glucose tolerance tests (GTT) were performed before mice were killed for blood samples and tissue collection. A:
Body weight of low-fat diet–fed mice. B: Body weight of high-fat diet–fed mice. C: Accumulated food intake of low-fat diet–fed mice. D:
Accumulated food intake of high-fat diet–fed mice. E: Body fat of low-fat diet–fed mice. F: Body fat of low-fat diet–fed mice. G: Glucose tolerance
test of low-fat diet–fed mice. H: Glucose tolerance test of low-fat diet–fed mice. Data are presented as means  SE. *P < 0.05, t test comparing
Ffar1
/ and Ffar1
/ mice at each time point.
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3002 DIABETES, VOL. 57, NOVEMBER 2008fatty acid–stimulated insulin secretion. Amylin release was
attenuated in Ffar1
/ mice as well, following the same
pattern as that of insulin (Fig. 2C). The 10-fold increase
of insulin in Ffar1
/ mice in response to CL-316,243
could conceivably be due to a direct stimulation of 3-
adrenergic receptor–mediated nerve signaling in the pan-
creatic islets, or it could be mediated indirectly through
other adipose or gut-derived hormones, such as leptin or
GLP-1. We examined whether leptin or GLP-1 release was
affected by CL-316,243. Plasma leptin levels were unaf-
fected (Fig. 2D, P 
 0.61, ANOVA). For GLP-1, there was a
signiﬁcant difference among the treatment groups as as-
sessed by ANOVA (P 
 0.046); however, t tests failed to
reach statistical signiﬁcance after adjusting for multiple
comparisons. Nevertheless, on pairwise comparison,
GLP-1 levels increased by approximately twofold in CL-
316,243–treated Ffar1
/ mice compared with saline-
treated mice (Fig. 2E; P 
 0.02, Ffar1
/ CL-316,243 vs.
Ffar1
/ saline, one-tailed t test). In the CL-316,243–
treated groups, Ffar1
/ mice had lower GLP-1 levels
when compared with the Ffar1
/ mice (P 
 0.04,
Ffar1
/ CL-316,243 vs. Ffar1
/ CL-316,243, one-tailed t
test). Finally, because it was reported that FFAR1 is
expressed and active in pancreatic -cells (11), we tested
the effect of CL-316,243 treatment on glucagon secretion.
As shown in Fig. 2F, glucagon levels increased on CL-
316,243 treatment (P 	 0.05, t test with Bonferroni correc-
tion), and among the CL-316,243–treated groups, Ffar1
/
mice had lower glucagon levels than the Ffar1
/ mice
(Fig. 2F; P 	 0.05, t test with Bonferroni correction).
Ffar1
/ mice were not protected from high-fat diet–
induced metabolic complications. In light of the previ-
ous report by Steneberg et al. (5), we asked whether our
Ffar1
/ mice are protected from developing insulin re-
sistance under metabolic stress. We ﬁrst carried out a pilot
study using mice on a mixed B6/129 background and a
modest high-fat diet (45% calories from fat; Research
Diets). We failed to observe any difference in obesity-
associated phenotypes between Ffar1
/ and Ffar1
/
mice (data not shown). To test the possibility that different
high-fat diet formulas might have led to a different pheno-
type than that observed by Steneberg et al. (5), we
obtained the same diet they used (Surwit Diabetogenic
Diet, 58% kcal Lard Diet; custom-made through Research
Diets) and an appropriate control semipuriﬁed low-fat diet
(D12450B; 10% of calories from fat; Research Diets). We
placed ﬁve mice of each genotype (total 20 mice; 7–8
weeks old) on either a high-fat or low-fat diet for 8 weeks.
The Ffar1
/ mice on the 10% low-fat diet were heavier
than the Ffar1
/ mice on the same diet (Fig. 3A),
whereas the mice selected for 58% high-fat diet did not
show a signiﬁcant difference (Fig. 3B). Ffar1
/ mice had
slightly but signiﬁcantly higher accumulated food intake
than the Ffar1
/ mice on a low-fat diet (Fig. 3C). On a
high-fat diet, Ffar1
/ mice also showed more accumu-
lated food intake at weeks 2 and 3 (Fig. 3D); however, for
the later time points, the differences did not reach statis-
tical signiﬁcance (P values by t tests were between 0.05
and 0.10 for each of those time points) (Fig. 3D). Through-
out the time course, the body fat percentages were com-
parable between Ffar1
/ and Ffar1
/ mice (Fig. 3E and
F). Glucose tolerance and insulin tolerance tests were
performed after the mice were put on a diet for 8 weeks.
In contrast to what was reported by Steneberg et al. (5),
Ffar1
/ mice did not exhibit improved glucose tolerance
when fed either the low-fat diet (Fig. 3G) or high-fat diet
(Fig. 3H).
At the end of the diet study, we measured plasma
metabolic parameters using samples collected from termi-
nal bleeds (Table 1). We used two-way ANOVA to analyze
the differences attributed to diet and genotype effects. If
there was a signiﬁcant genotypic effect, we then used
pairwise t tests to examine whether the difference was
attributed to a low-fat diet or high-fat diet. We did not
observe a diet or a genotypic effect on plasma glucose. The
glucose levels were high in all the groups, likely as a result
of postprandial terminal bleeding. There was a signiﬁcant
diet effect, but not a genotypic effect, on insulin (Table 1;
P 
 0.02). Both Ffar1
/ and Ffar1
/ mice had compa-
rable insulin levels on the high-fat diet, and the insulin
levels between the Ffar1
/ and Ffar1
/ mice on the
low-fat diet were not signiﬁcantly different (P 
 0.11,
pairwise t test). The data indicate that Ffar1
/ mice were
not protected from high-fat diet–induced hyperinsulin-
emia. Plasma cholesterol levels were also higher in high-
fat diet–fed mice, and there was no genotypic effect.
Interestingly, there was a genotypic effect on plasma
triglycerides (P 
 0.02, two-way ANOVA). The effect was
attributed to the fact that the Ffar1
/ mice had lower
plasma triglyceride levels on the low-fat diet (P 
 0.03, t
test), but not on the high-fat diet (P 
 0.31, t test).
Conversely, the liver triglyceride levels were higher in the
TABLE 1
Plasma and liver parameters of Ffar1
/ and Ffar1
/ mice after 8 weeks on 10% low-fat diet and 58% high-fat diet
Low-fat diet High-fat diet P value
Ffar1
/ Ffar1
/ Ffar1
/ Ffar1
/ Diet Genotype
n 5555
Plasma glucose (mg/dl) 227  18 236  6 236  16 230  17 NS NS
Plasma insulin (ng/ml) 0.79  0.18 1.76  0.52 3.54  1.13 3.78  1.13 0.02 NS
Plasma total cholesterol (mg/dl) 108.6  5.4 124.8  7.6 138.5  6.6 139.1  9.1 	0.01 NS
Plasma triglyceride (mg/dl) 68.6  4.5 48.1  6.8 63.4  5.8 55.6  5.2 NS 0.02
Liver cholesterol ester (mg/g tissue) 6.37  0.63 8.34  0.79 5.65  0.43 6.06  0.21 0.02 0.05
Liver triglyceride (mg/g tissue) 62.2  9.8 122  20 226  47 301  60 NS 	0.01
Liver free cholesterol (mg/g tissue) 1.92  0.10 1.64  0.19 1.34  0.13 1.71  0.11 NS NS
Liver weight (g) 1.11  0.07 1.54  0.06 1.21  0.06 1.33  0.11 NS 0.02
Liver cholesterol ester (mg/liver) 7.09  0.87 12.95  1.61 6.74  0.36 8.10  0.86 0.02 	0.01
Liver triglyceride (mg/liver) 71.3  15.9 193  39 281  72 421  104 	0.01 NS
Liver free cholesterol (mg/liver) 2.10  0.02 2.51  0.25 1.59  0.10 2.23  0.14 0.02 	0.01
Data are means  SE. The P values are generated by two-way ANOVA testing diet and genotype effects.
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/ mice on a low-fat diet (P 
 0.03, t test). High-fat
diet increased liver triglyceride levels in both Ffar1
/ and
Ffar1
/ mice to a comparable level, so it is apparent that
Ffar1
/ mice were not protected from high-fat diet–
induced hepatic steatosis.
Because we were unable to reproduce the phenotype of
the Ffar1
/ mice using the 58% Surwit lard diet, we
carried out a third high-fat diet study using a semipuriﬁed
60% high-fat diet from Research Diets. In addition, to
eliminate contribution of a mixed genetic background, we
further backcrossed our mice into a B6 background for
more than 10 generations. Forty mice (Ffar1
/ male, n 

11; Ffar1
/ male, n 
 9; Ffar1
/ female, n 
 10;
Ffar1
/ female, n 
 10) at 6–8 weeks of age were placed
on the 60% high-fat diet for 10 weeks. Metabolic charac-
terization was performed before and after the high-fat diet
treatment. As shown in Fig. 4, mice of both genotypes had
similar weight gain during the course of high-fat feeding
(Fig. 4A and B), and percentage of body fat did not differ
between Ffar1
/ and Ffar1
/ mice (Fig. 4C and D).
Again, Ffar1
/ mice did not show improvement on the
glucose tolerance test (Fig. 4E). No signiﬁcant differences
were observed between the genotypes at any of the time
points in the insulin tolerance test (Fig. 4F), and the areas
under the curves did not differ signiﬁcantly (13,449  881
vs. 11,845  1,170, P 
 0.28, t test). We also measured liver
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FIG. 4. Metabolic characterizations of Ffar1
/ and Ffar1
/ mice after 10 weeks on 60% high-fat diet (HFD). Ffar1
/ and Ffar1
/ mice after
10 generations of backcrossing into B6 background were fed for 10 weeks on semipuriﬁed high-fat diet (60% calories from fat). n  11, Ffar1
/
male; n  9, Ffar1
/ male; n  10, Ffar1
/ female; n  10, Ffar1
/ female. Body weight was monitored weekly, and body fat was assessed every
4 weeks. Glucose tolerance tests (GTT) and insulin tolerance tests (ITT) were performed at the end of the study. A: Body weight of male mice.
B: Body weight of female mice. C: Body fat of male mice. D: Body fat of female mice. E: GTT of male mice. F: ITT of male mice. Data are presented
as means  SE.
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contents were similar between Ffar1
/ and Ffar1
/
mice (Table 2). Although there were sex differences, no
genotypic difference was observed between Ffar1
/ and
Ffar1
/ mice of either sex. The data are consistent with
those in Table 1, conﬁrming that Ffar1
/ mice were not
protected from high-fat diet–induced hepatic steatosis.
DISCUSSION
Free fatty acids represent something of a Jekyll and Hyde
in regard to metabolic disease. Although an increase in
plasma fatty acid serves as one of the nutritional cues
leading to increased postprandial insulin secretion, the
long-term elevation of plasma free fatty acids observed in
obesity is thought to contribute to reduced insulin secre-
tion and ultimately islet dysfunction and the development
of type 2 diabetes. In this context, understanding the
function of FFAR1 as a cell surface receptor for fatty acids
becomes very important. To this end, we generated a line
of Ffar1
/ mice to use as a tool in studying this receptor.
The high-fat diet–induced phenotypes of our Ffar1
/
mice versus those reported by Steneberg et al. (5) were
very different. In the Steneberg et al. (5) report, Ffar1
/
mice fed the high-fat diet gained similar weight and had
reduced plasma glucose, insulin, and triglyceride levels
compared with Ffar1
/ mice. The mice also had dramat-
ically reduced hepatic steatosis as shown by histological
staining of a liver slice with oil red O. In addition, the mice
were reported to show improved glucose tolerance or
reduced glucose-stimulated insulin secretion and reduced
hepatic glucose output. Conversely, transgenic mice over-
expressing FFAR1 in pancreatic islets developed diabetes.
This led Steneberg et al. (5) to suggest that FFAR1 is
involved in the impairment of islet function induced by
chronic exposure of elevated fatty acid associated with
obesity. The data would also suggest that sustained signal-
ing through FFAR1, such as that achieved by pharmaco-
logical activation with FFAR1 agonists, might be
detrimental to diabetic patients. However, we were not
able to reproduce the protective phenotypes in our
Ffar1
/ mice using two distinct high-fat diets. Under the
same high-fat diet formula as those used by Steneberg et
al. (5), we observed that liver triglyceride and cholesterol
accumulated to a comparable degree in both Ffar1
/ and
Ffar1
/ mice, and no reduction of hepatic steatosis was
observed in the Ffar1
/ mice (Table 1). We reasoned that
because the 58% Surwit diet lacks certain unsaturated fatty
acids, it may not be the right diet to reﬂect a physiologi-
cally relevant setting. However, using a semipuriﬁed 60%
high-fat diet, we still did not observe a reduction of hepatic
steatosis in the Ffar1
/ mice. From the oil red O staining
in the Steneberg et al. study (5), it was not clear whether
the reduced liver fat accumulation in the Ffar1
/ mice
was statistically signiﬁcantly lower than that in the
Ffar1
/ mice.
The cause of the discrepancy between our study and
that of Steneberg et al. (5) is not clear. One possibility may
be a difference in genetic backgrounds. Our mice, although
generated in a hybrid background, were backcrossed to B6
mice. The 58% high-fat diet study was carried out with
mice that were backcrossed for six generations; the 60%
high-fat diet study used mice backcrossed for 10 gener-
ations. The genetic background of the mice in the
Steneberg et al. study (5) was reported as “backcrossed
several generations.“ Another possibility is that FFAR1
may play a role maintaining basal metabolic homeostasis,
but its effects are masked out by high-fat diet–induced
metabolic stress. In our studies, we observed some detri-
mental phenotypes of the Ffar1
/ mice on a low-fat diet.
For example, our Ffar1
/ mice had higher liver triglyc-
eride (P 
 0.03) on the low-fat diet (Table 1). The Ffar1
/
mice were also heavier, and they had slightly more food
intake (Fig. 3). The results suggest that Ffar1
/ mice may
have an unfavorable metabolic proﬁle at basal conditions.
Latour et al. (7) reported that 13-week-old male Ffar1
/
mice on chow diet had a signiﬁcant albeit small degree of
glucose intolerance. We speculate that because Ffar1
/
mice have a poorer proﬁle than the Ffar1
/ mice to begin
with, when they reach the same metabolic endpoints on a
high-fat diet, the high-fat diet–induced “net change” could
be viewed as smaller in the Ffar1
/ mice, and the smaller
change could be interpreted as resistance to a high-fat
diet. However, it should be emphasized that, based on the
detrimental phenotypes of Ffar1
/ mice in the present
study and the glucose intolerance data from Latour et al.
(7), deletion of FFAR1 does not decrease (rather, it likely
increases) the risk of metabolic disease on either low-fat
diet or high-fat diet.
Another controversy in the literature is whether FFAR1
mediates the negative effects of chronic elevated fatty
acids on insulin secretion and insulin resistance and
whether FFAR1 links obesity and insulin resistance.
Steneberg et al. (5) showed that insulin secretion from
isolated Ffar1
/ islets was not impaired by 48-h exposure
to palmitic acid and concluded that Ffar1
/ islets are
protected from the long-term negative effect of fatty acids.
They suggested that FFAR1 mediates the long-term nega-
tive effects of fatty acids and proposed that FFAR1 antag-
onism may represent a therapeutic strategy for obesity-
associated type 2 diabetes. In contrast, Latour et al. (7)
TABLE 2
Liver lipids of Ffar1
/ and Ffar1
/ mice after 10 weeks on a 60% high-fat diet
Male Female P value
Ffar1
/ Ffar1
/ Ffar1
/ Ffar1
/ Sex Genotype
n 1 191 0 1 0
Liver cholesterol ester (mg/g tissue) 4.42  0.80 4.88  1.03 4.48  0.15 5.03  0.33 NS NS
Liver triglyceride (mg/g tissue) 485  47 552  67 293  14 309  32 	0.01 NS
Liver free cholesterol (mg/g tissue) 1.36  0.06 1.44  0.08 1.46  0.03 1.54  0.04 NS NS
Liver weight (g) 1.85  0.12 2.09  0.22 1.42  0.06 1.35  0.07 	0.01 NS
Liver cholesterol ester (mg/liver) 8.34  1.68 11.1  3.1 6.35  0.35 6.76  0.50 	0.01 NS
Liver triglyceride (mg/liver) 929  117 1251  219 424  35 435  665 	0.01 NS
Liver free cholesterol (mg/liver) 2.52  0.21 2.99  0.37 2.07  0.09 2.07  0.09 	0.01 NS
Data are means  SE. The P values are generated by two-way ANOVA testing sex and genotype effect.
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/ mice were still
subject to the impairment of the insulin response after
chronic exposure to fatty acids and suggested that FFAR1
mediates the acute effect of fatty acids on insulin secretion
but not the chronic, deleterious effects. Additionally,
Ffar1
/ mice have approximately one-half the acute
insulin secretion in vivo in response to a bolus of injected
Intralipid. Although the objective of our study was to
examine the effects of high-fat diet on Ffar1
/ mice, we
did conﬁrm that FFAR1 mediates acute fatty acid–stimu-
lated insulin release in vivo. FFAR1 does not play a role in
adipose tissue lipolysis or leptin release, but it can affect
GLP-1 level. Finally, CL-316,243 treatment stimulated glu-
cagon release, and such an effect was attenuated in
Ffar1
/ mice (Fig. 3F), supporting a previous report that
FFAR1 is expressed in glucagon-producing cells and that it
affects glucagon secretion (11).
While the present manuscript was in revision, three new
studies appeared in press in Diabetes addressing the roles
of GPR40/FFAR1 in insulin secretion and metabolic ho-
meostasis. The ﬁrst study by Tan et al. (12) showed that
selective small-molecule agonists of FFAR1 promoted
glucose-dependent insulin secretion and reduced blood
glucose in Ffar1
/ but not in Ffar1
/ mice, and they
concluded that FFAR1 does not mediate the long-term
effects of fatty acids on islet function. Our results support
these ﬁndings. The second study by Edfalk et al. (13)
showed that Ffar1 is expressed in enteroendocrine cells
and mediates fatty acid stimulation of incretin secretion.
Our data support a possible involvement of FFAR1 in fatty
acid–mediated GLP-1 secretion. Finally, the study by
Kebede et al. (14) examined the role of FFAR1 in insulin
secretion in vivo after high-fat feeding. They reported that
Ffar1
/ mice had fasting hyperglycemia despite normal
glucose and insulin tolerance. Ffar1
/ mice became as
obese, became as glucose intolerant and as insulin resis-
tant as their Ffar1
/ littermates under high-fat diet (60%
fat), and developed a similar degree of liver steatosis (14).
Our results are consistent with those in the Kebede et al.
study (14). We also show that Ffar1
/ mice had slightly
more food intake and body weight on a low-fat diet. In
addition, we provide quantitative data showing that livers
of Ffar1
/ mice accumulate no less neutral lipids than
Ffar1
/ littermates under either low-fat diet or high-fat
diet.
In conclusion, the present study demonstrates that
FFAR1 contributes to the maintenance of basal metabo-
lism and that deletion of FFAR1 does not protect mice
from high-fat diet–induced metabolic disease. Our results,
along with those of the recently published studies (7,12–
14), jointly argue that antagonists of FFAR1 may not
provide signiﬁcant beneﬁt for obesity-associated type 2
diabetes.
ACKNOWLEDGMENTS
Schering-Plough Research Institute is fully funded by
Schering-Plough Corporation.
We are grateful for the technical support from Andrei
Golovko on gene expression and from Ling Pang on insulin
analysis. We thank Drs. Timothy Kowalski and Ruth Duffy
for critical discussions and Drs. Marvin Bayne and Michael
Graziano for administrative support.
REFERENCES
1. Brown AJ, Jupe S, Briscoe CP: A family of fatty acid binding receptors.
DNA Cell Biol 24:54–61, 2005
2. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, Ogi K,
Hosoya M, Tanaka Y, Uejima H, Tanaka H, Maruyama M, Satoh R, Okubo
S, Kizawa H, Komatsu H, Matsumura F, Noguchi Y, Shinohara T, Hinuma
S, Fujisawa Y, Fujino M: Free fatty acids regulate insulin secretion from
pancreatic beta cells through GPR40. Nature 422:173–176, 2003
3. Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M,
Sugimoto Y, Miyazaki S, Tsujimoto G: Free fatty acids regulate gut incretin
glucagon-like peptide-1 secretion through GPR120. Nat Med 11:90–94, 2005
4. Winzell MS, Ahren B: G-protein-coupled receptors and islet function:
implications for treatment of type 2 diabetes. Pharmacol Ther 116:437–
448, 2007
5. Steneberg P, Rubins N, Bartoov-Shifman R, Walker MD, Edlund H: The
FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and im-
paired glucose homeostasis in mouse. Cell Metab 1:245–258, 2005
6. Unger RH: Lipotoxic diseases. Annu Rev Med 53:319–336, 2002
7. Latour MG, Alquier T, Oseid E, Tremblay C, Jetton TL, Luo J, Lin DC,
Poitout V: GPR40 is necessary but not sufﬁcient for fatty acid stimulation
of insulin secretion in vivo. Diabetes 56:1087–1094, 2007
8. Susulic VS, Frederich RC, Lawitts J, Tozzo E, Kahn BB, Harper ME,
Himms-Hagen J, Flier JS, Lowell BB: Targeted disruption of the beta
3-adrenergic receptor gene. J Biol Chem 270:29483–29492, 1995
9. Burrier RE, Deren S, McGregor DG, Hoos LM, Smith AA, Davis HR Jr:
Demonstration of a direct effect on hepatic acyl CoA: cholesterol acyl
transferase (ACAT) activity by an orally administered enzyme inhibitor in
the hamster. Biochem Pharmacol 47:1545–1551, 1994
10. Umekawa T, Yoshida T, Sakane N, Kondo M: Effect of CL316,243, a highly
speciﬁc beta 3-adrenoceptor agonist, on lipolysis of human and rat
adipocytes. Horm Metab Res 28:394–396, 1996
11. Flodgren E, Olde B, Meidute-Abaraviciene S, Winzell MS, Ahren B, Salehi
A: GPR40 is expressed in glucagon producing cells and affects glucagon
secretion. Biochem Biophys Res Commun 354:240–245, 2007
12. Tan CP, Feng Y, Zhou YP, Eiermann GJ, Petrov A, Zhou C, Lin S, Salituro
G, Meinke P, Mosley R, Akiyama TE, Einstein M, Kumar S, Berger JP, Mills
SG, Thornberry NA, Yang L, Howard AD: Selective small-molecule agonists
of G protein-coupled receptor 40 promote glucose-dependent insulin
secretion and reduce blood glucose in mice. Diabetes 57:2211–2219, 2008
13. Edfalk S, Steneberg P, Edlund H: Gpr40 is expressed in enteroendocrine
cells and mediates FFA stimulation of incretin secretion. Diabetes 57:
2280–2287, 2008
14. Kebede M, Alquier T, Latour MG, Semache M, Tremblay C, Poitout V: The
fatty-acid receptor GPR40 plays a role in insulin secretion in vivo after
high-fat feeding. Diabetes 57:2432–2437, 2008
Ffar1
/ MICE DEVELOP METABOLIC DISEASE
3006 DIABETES, VOL. 57, NOVEMBER 2008